Market Place
Sourcing Support
Alembic Gets USFDA Tentative Approval For Selexipag Injection
14 Jul 2024 //
INDIANPHARMAPOST
Johnson & Johnson 1Q Results
20 May 2024 //
CONTRACT PHARMA
Cipla`s Generic Selexipag Receives Approval in the U.S.
11 Mar 2024 //
FDA
Zydus` Generic Selexipag Receives Approval in the U.S.
21 Dec 2022 //
FDA
FDA Confirms Paragraph IV Patent Litigation for Uptravi (Selexipag)
22 Sep 2022 //
FDA
Zydus receives tentative approval from US FDA for Selexipag tablets
06 May 2022 //
EXPRESS PHARMA
SPIL`s Generic Amphotericin B Receives Approval in the U.S.
13 Dec 2021 //
FDA
Alembic Pharm`s Generic Selexipag Receives Approval in the U.S.
07 Dec 2021 //
FDA
New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in PAH
30 Aug 2021 //
BUSINESSWIRE
TRITON Phase 3b Study Results Presented at the European Society of Cardiology
31 Aug 2020 //
BUSINESSWIRE
NHS England to fund Actelion`s Uptravi
03 Jan 2019 //
United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug
16 Nov 2018 //
ENDPTS
PAH patients in England denied access to Actelion’s Uptravi on NHS
09 Jul 2018 //
PHARMA TIMES
Five therapies endorsed for use on NHS Scotland
08 May 2018 //
PARMA TIMES
EMA Completes Postmarket Safety Review of Uptravi
08 Apr 2017 //
RAPS
EMA panel recommends that use of Actelion`s Uptravi may continue
11 Feb 2017 //
REUTERS
Johnson & Johnson May Never Recoup Its Costs to Buy Actelion
28 Jan 2017 //
MOTLEY FOOL
Actelion Fails Key PhIII, but Investors Brush it off as J&J Megadeal Draws Near
24 Jan 2017 //
FIERCE PHARMA
J&J Discussing Breaking up Actelion in an Acquisition
30 Dec 2016 //
REUTERS
Actelion`s ambitious independent-minded CEO will drive up takeover price
28 Nov 2016 //
REUTERS
Actelion hikes core profit guidance after strong first-half
21 Jul 2016 //
REUTERS
European approval for Actelion`s Uptravi in PAH
17 May 2016 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.